EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY-NC 4.0

Real‐World Outcomes of Midostaurin Plus Intensive Chemotherapy in FLT3 ‐Mutated AML: The PETHRATIFY Study

Mónica Alejandra Romero Riquelme, Gaspar Aspas Requena iD, Pilar Lloret-Madrid, Cristina Gil iD, Eliana Aguiar iD, Mar Tormo iD, Teresa Del Bernal Del Castillo iD, Eduardo Rodríguez Arbolí iD, Josefina Serrano iD, Joaquín Sánchez-García, Carlos Rodríguez-Medina, José Mário Mariz iD und 38 weitere

American Journal of Hematology · 2026

DOI: 10.1002/ajh.70488 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift American Journal of Hematology, 2026. Verfasst von Mónica Alejandra Romero Riquelme und 49 weiteren Autor:innen. Beteiligte Einrichtung: Hospital Guillermo Grant Benavente de Concepción, Concepción, Chile. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, fms-Like Tyrosine Kinase 3, Leukemia, Myeloid, Acute, Mutation. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mutations in FLT3 are present in approximately 30% of patients with AML. The addition of midostaurin (MIDO) to intensive chemotherapy (IC) became standard of care following the RATIFY trial, but comprehensive real‐world data spanning the full adult age spectrum and including both FLT3 ‐ITD and FLT3 ‐TKD mutations remain limited. We retrospectively analyzed 1658 adults aged 14–85 years with newly diagnosed FLT3 ‐mutated AML from 129 PETHEMA registry centers: 469 received IC + MIDO and 1189 IC alone. Composite complete remission was higher with IC + MIDO than IC (81.4% vs. 71.7%; p < 0.001) and Day 30 mortality was substantially lower (2.1% vs. 7.1%; p < 0.001). Median overall survival was 47.2 versus 19.3 months (HR 0.64; 95% CI, 0.53–0.76; p < 0.001), and the benefit was sustained after multivariable adjustment (HR 0.73; p = 0.017). In 261 propensity score–matched pairs, the effect was attenuated, remaining significant for event‐free survival (HR 0.77; p = 0.029) and showing a nonsignificant trend for OS (HR 0.77; p = 0.06). Allogeneic hematopoietic stem cell transplantation in first remission was more frequent in the IC + MIDO cohort (48.9% vs. 41.3%; p = 0.023). Time‐dependent analyses showed the largest MIDO effect among autologous and non‐transplanted patients (OS HR 0.45; p = 0.138, and HR 0.69; p = 0.014, respectively). The benefit of MIDO was consistent irrespective of FLT3 mutation type, FLT3 ‐ITD allelic burden, cytogenetic risk, and gender, while less improvement occurred among NPM1 wild type and secondary AML patients. This large real‐world cohort confirms the survival benefit of MIDO plus IC across the full adult age spectrum, supporting its standard‐of‐care status in FLT3 ‐mutated AML.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy Protocolsfms-Like Tyrosine Kinase 3Leukemia, Myeloid, AcuteMutationStaurosporineAdolescentAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedYoung AdultNucleophosminRegistriesRemission InductionRetrospective StudiesTreatment Outcome

Stichwörter der Autor:innen

FLT3‐mutatedacute myeloid leukemiafront‐linemidostaurinreal‐world

Substanzen

FLT3 protein, humanfms-Like Tyrosine Kinase 3midostaurinNPM1 protein, humanNucleophosminStaurosporine

Autor:innen und Institutionen

  • Hospital Guillermo Grant Benavente de Concepción, Concepción, Chile.
  • Department of Hematology, University Hospital of Montpellier, Montpellier, France.
  • Hospital Universitario y Politécnico La Fe, Valencia, Spain.
  • Hospital General Universitario de Alicante, Alicante, Spain.
  • Centro Hospitalar São João, Porto, Portugal.
  • Hospital Clínico Universitario de Valencia, Valencia, Spain.

ORCID-Profile: Gaspar Aspas Requena, Cristina Gil, Eliana Aguiar, Mar Tormo, Teresa Del Bernal Del Castillo, Eduardo Rodríguez Arbolí, Josefina Serrano, José Mário Mariz, Rosa Ayala, Joaquín Martínez-López, Susana Vives, Lorenzo Algarra Algarra, Raimundo García Boyero, Joana Brioso, Juan M Bergua Burgués, María García Fortes, María José Sayas Lloris, Belén Vidriales Vicente, Jorge Labrador Gómez, María José García Pérez, Manuel Pérez Encinas, Amaia Balerdi Malcorra, Pilar Herrera Puente, Olga Arce Fernández, Manuel Barrios García, Mamen Mateos, Pau Montesinos

Zitieren

APA

Romero Riquelme, M. A., Aspas Requena, G., Lloret-Madrid, P., Gil, C., Aguiar, E., Tormo, M., Del Bernal Del Castillo, T., Rodríguez Arbolí, E., Serrano, J., Sánchez-García, J., Rodríguez-Medina, C., Mariz, J. M., Ayala, R., Martínez-López, J., Amigo, M. L., Vives, S., Algarra Algarra, L., García Boyero, R., Brioso, J., …, & Montesinos, P. (2026). Real‐World Outcomes of Midostaurin Plus Intensive Chemotherapy in FLT3 ‐Mutated AML: The PETHRATIFY Study. American Journal of Hematology. https://doi.org/10.1002/ajh.70488

Vancouver

Romero Riquelme MA, Aspas Requena G, Lloret-Madrid P, Gil C, Aguiar E, Tormo M, et al. Real‐World Outcomes of Midostaurin Plus Intensive Chemotherapy in FLT3 ‐Mutated AML: The PETHRATIFY Study. American Journal of Hematology. 2026. doi:10.1002/ajh.70488

BibTeX
@article{RomeroRiquelme2026,
  author = {Romero Riquelme, Mónica Alejandra and Aspas Requena, Gaspar and Lloret-Madrid, Pilar and Gil, Cristina and Aguiar, Eliana and Tormo, Mar and Del Bernal Del Castillo, Teresa and Rodríguez Arbolí, Eduardo and Serrano, Josefina and Sánchez-García, Joaquín and Rodríguez-Medina, Carlos and Mariz, José Mário and Ayala, Rosa and Martínez-López, Joaquín and Amigo, María Luz and Vives, Susana and Algarra Algarra, Lorenzo and García Boyero, Raimundo and Brioso, Joana and Castaño, Tamara and Bergua Burgués, Juan M and Salamero, Olga and Bass Maturana, María Francisca and Colorado, Mercedes and García Fortes, María and Sayas Lloris, María José and Vicente, Belén Vidriales and Chillón, Carmen and Pérez Santaolalla, Esther and Madrigal, María Dolores and Labrador Gómez, Jorge and García Pérez, María José and Casado Calderón, Soledad and Pérez Encinas, Manuel and Balerdi Malcorra, Amaia and Rodríguez, María Solé and Gómez García, Lara María and Herrera Puente, Pilar and Arce Fernández, Olga and Barrios García, Manuel and Noriega, Víctor and Fernández, Rosa and Mateos, Mamen and Lacalzada, Carolina and Almela Gallego, Ágata and García Garay, María Carmen and Couto, Carmen and Pérez-Simón, José Antonio and Barragán González, Eva and Montesinos, Pau},
  title = {Real‐World Outcomes of Midostaurin Plus Intensive Chemotherapy in FLT3 ‐Mutated AML: The PETHRATIFY Study},
  journal = {American Journal of Hematology},
  year = {2026},
  doi = {10.1002/ajh.70488}
}
Kostenlos starten →